Proof of principle concept for the analysis and functional prediction of rare genetic variants in the CYP2C19 and CYP2D6 genes

被引：0
作者：
Inger Johansson [1 ]
Yuchen Lu [1 ]
Yitian Zhou [1 ]
Kristi Krebs [2 ]
Martina Akcan [3 ]
Lili Milani [1 ]
Magnus Ingelman-Sundberg [3 ]
机构：
[1] Karolinska Institutet,Department of Physiology and Pharmacology
[2] Karolinska Institutet and Karolinska University Hospital,Center for Molecular Medicine
[3] University of Tartu,Estonian Genome Centre, Institute of Genomics
来源：
Human Genomics | / 19卷 / 1期
关键词：
Pharmacogenomics; Clopidogrel; Omeprazole; Antidepressants; Antipsychotics;
D O I：
10.1186/s40246-025-00765-2
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] The Utility of CYP2D6 and CYP2C19 Variants to Guide Pharmacological Treatment in Complex Unipolar Major Depression: A Pilot Longitudinal Study
    Reshma Ramaraj
    Zeina N. Al-Mahayri
    Reema Saleous
    Karim Abdel Aziz
    Fadwa Al-Mugaddam
    Mouza Al-Sabousi
    Aysha Alhassani
    Noura Ali Al Ahbabi
    Emmanuel Stip
    George P. Patrinos
    Bassam R. Ali
    Danilo Arnone
    Psychiatric Quarterly, 2023, 94 : 435 - 447
  • [12] Clinical Impact of Functional CYP2C19 and CYP2D6 Gene Variants on Treatment with Antidepressants in Young People with Depression: A Danish Cohort Study
    Thiele, Liv S.
    Ishtiak-Ahmed, Kazi
    Thirstrup, Janne P.
    Agerbo, Esben
    Lunenburg, Carin A. T. C.
    Muller, Daniel J.
    Gasse, Christiane
    PHARMACEUTICALS, 2022, 15 (07)
  • [13] Influence of CYP2C19 and CYP2D6 on side effects of aripiprazole and risperidone: A systematic review
    de Brabander, Emma
    Schaars, Kristian Kleine
    van Amelsvoort, Therese
    van Westrhenen, Roos
    JOURNAL OF PSYCHIATRIC RESEARCH, 2024, 174 : 137 - 152
  • [14] Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting
    Bousman, Chad A.
    Jaksa, Philip
    Pantelis, Christos
    PHARMACOGENETICS AND GENOMICS, 2017, 27 (11) : 387 - 393
  • [15] Association of CYP2D6 and CYP2C19 metabolizer status with switching and discontinuing antidepressant drugs: an exploratory study
    Brouwer, Jurriaan M. J. L.
    Wardenaar, Klaas J.
    Nolte, Ilja M.
    Liemburg, Edith J.
    Bet, Pierre M.
    Snieder, Harold
    Mulder, Hans
    Cath, Danielle C.
    Penninx, Brenda W. J. H.
    BMC PSYCHIATRY, 2024, 24 (01)
  • [16] Pharmacogenetics of Long-Term Outcomes of Schizophrenia Spectrum Disorders: The Functional Role of CYP2D6 and CYP2C19
    Sandhu, Amrit K.
    Naderi, Elnaz
    Wijninga, Morenika J.
    Liemburg, Edith J.
    Cath, Danielle
    Bruggeman, Richard
    Alizadeh, Behrooz Z.
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (09):
  • [17] Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
    Li-Wan-Po, Alain
    Girard, Thierry
    Farndon, Peter
    Cooley, Candy
    Lithgow, James
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 69 (03) : 222 - 230
  • [18] Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors
    Spigset, O
    Hedenmalm, K
    Dahl, ML
    Wiholm, BE
    Dahlqvist, R
    ACTA PSYCHIATRICA SCANDINAVICA, 1997, 96 (05) : 379 - 384
  • [19] In Vitro Functional Characterisation of Cytochrome P450 (CYP) 2C19 Allelic Variants CYP2C19*23 and CYP2C19*24
    Lau, Pui Shen
    Leong, Kenny Voon Gah
    Ong, Chin Eng
    Dong, Amelia Nathania Hui Min
    Pan, Yan
    BIOCHEMICAL GENETICS, 2017, 55 (01) : 48 - 62
  • [20] Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients
    Serretti, Alessandro
    Calati, Raffaella
    Massat, Isabelle
    Linotte, Sylvie
    Kasper, Siegfried
    Lecrubier, Yves
    Sens-Espel, Roser
    Bollen, Joseph
    Zohar, Joseph
    Berlo, Jacques
    Lienard, Patricia
    De Ronchi, Diana
    Mendlewicz, Julien
    Souery, Daniel
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2009, 24 (05) : 250 - 256
12345